Oral probiotics in coronavirus disease 2019: connecting the gut–lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials

Piyush Baindara,Ranadhir Chakraborty,Zachary M. Holliday,Santi M. Mandal,Adam G. Schrum,P. Baindara,R. Chakraborty,Z.M. Holliday,S.M. Mandal,A.G. Schrum
DOI: https://doi.org/10.1016/j.nmni.2021.100837
2021-03-01
New Microbes and New Infections
Abstract:Defined as helpful live bacteria that can provide medical advantages to the host when administered in tolerable amounts, oral probiotics might be worth considering as a possible preventive or therapeutic modality to mitigate coronavirus disease 2019 (COVID-19) symptom severity. This hypothesis stems from an emerging understanding of the gut-lung axis wherein probiotic microbial species in the digestive tract can influence systemic immunity, lung immunity, and possibly viral pathogenesis and secondary infection co-morbidities. We review the principles underlying the gut-lung axis, examples of probiotic-associated antiviral activities, and current clinical trials in COVID-19 based on oral probiotics.
What problem does this paper attempt to address?